Notable Labs

Notable Labs FCF/Net Income

The Free Cash Flow to Net Income Ratio of Notable Labs (NTBLQ) as of Nov 8, 2026 is 122.35 %. In the previous year, Free Cash Flow to Net Income Ratio was 100.31 % — a change of 21.97% (higher).

FCF/Net Income

122.35 %

YoY

21.97%

Last updated:

Free Cash Flow to Net Income Ratio of Notable Labs is 2023 122.35 % . Free Cash Flow to Net Income Ratio of Notable Labs was 2022 100.31 % . It decreases by 21.97% higher compared to the previous year.

The Notable Labs FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2016
86.88 USD
Jan 1, 2017
101.58 USD
Jan 1, 2018
87.37 USD
Jan 1, 2019
67.84 USD
Jan 1, 2020
96.70 USD
Jan 1, 2021
88.40 USD
Jan 1, 2022
100.31 USD
Jan 1, 2023
122.35 USD
The Notable Labs FCF/Net Income history
YEARFCF/Net IncomeYoY
122.35 %+21.97%
100.31 %+13.47%
88.40 %-8.58%
96.70 %+42.55%
67.84 %-22.36%
87.37 %-13.99%
101.58 %+16.92%
86.88 %-2.67%
89.25 %+12.93%
79.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Free Cash Flow to Net Income Ratio of Notable Labs is 122.35 % in 2023.

Free Cash Flow to Net Income Ratio of Notable Labs changed from 100.31 % to 122.35 %, representing a 21.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Notable Labs since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Notable Labs

All Key Metrics — Notable Labs